Lotus Pharmaceutical Co., Ltd. (TPE: 1795)

Market Cap	71.39B
Revenue (ttm)	17.59B
Net Income (ttm)	4.33B
Shares Out	265.39M
EPS (ttm)	16.48
PE Ratio	16.32
Forward PE	12.03
Dividend	4.65 (1.76%)
Ex-Dividend Date	Aug 5, 2024

Volume	945,869
Open	266.00
Previous Close	264.50
Day's Range	266.00 - 273.00
52-Week Range	210.50 - 347.00
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 14, 2025

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemica...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2023, Lotus Pharmaceutical's revenue was 16.96 billion, an increase of 15.89% compared to the previous year's 14.63 billion. Earnings were 4.11 billion, an increase of 35.91%.